Literature DB >> 15842664

UTY-specific TCR-transfer generates potential graft-versus-leukaemia effector T cells.

Roman Ivanov1, Samantha Hol, Tineke Aarts, Anton Hagenbeek, Elisabeth H Slager, Saskia Ebeling.   

Abstract

Immunotherapeutic approaches that target antigens that are differentially recognized on haematopoietic and non-haematopoietic cells may specifically enhance the graft-versus-leukaemia (GVL) effect of donor lymphocyte infusion. In this study, we have characterized a new HLA-B*5201-restricted epitope of the UTY gene. Unusually, presentation of this epitope was restricted to lymphoblasts. As a result, a T cell clone specific to this epitope recognized normal and malignant male B and T lymphoblasts, while showing little reactivity towards male HLA-B*5201+ fibroblasts. Transfer of its T cell receptor (TCR) into donor T cells led to the generation of large numbers of T cells, which acquired the specificity of the original clone, its avidity and the differential pattern of reactivity towards lymphoblasts and fibroblasts. Remarkably, the specific response of TCR-transferred T cells was significantly higher than that of the original clone. This is the first demonstration of the possibility to preserve the specific pattern of a T cell response to a differentially expressed antigen after TCR-transfer and to augment the amplitude of this response concomitantly. These results indicate that it may be feasible to enhance the GVL effect of donor lymphocyte infusions in lymphoproliferative malignancies by the transfer of TCRs specific to epitopes that are differentially recognized on lymphoblasts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15842664     DOI: 10.1111/j.1365-2141.2005.05461.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens.

Authors:  R Ivanov; S Hol; T I Aarts; A Hagenbeek; S B Ebeling
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 2.  Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation.

Authors:  John A Hansen; Jason W Chien; Edus H Warren; Lue Ping Zhao; Paul J Martin
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

3.  DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells.

Authors:  Kellie V Rosinski; Nobuharu Fujii; Jeffrey K Mito; Kevin K W Koo; Suzanne M Xuereb; Olga Sala-Torra; James S Gibbs; Jerald P Radich; Yoshiki Akatsuka; Benoît J Van den Eynde; Stanley R Riddell; Edus H Warren
Journal:  Blood       Date:  2008-02-25       Impact factor: 22.113

4.  Association of Y chromosome haplogroup I with HIV progression, and HAART outcome.

Authors:  Efe Sezgin; Joanne M Lind; Sadeep Shrestha; Sher Hendrickson; James J Goedert; Sharyne Donfield; Gregory D Kirk; John P Phair; Jennifer L Troyer; Stephen J O'Brien; Michael W Smith
Journal:  Hum Genet       Date:  2009-01-24       Impact factor: 4.132

Review 5.  Targeting cancers through TCR-peptide/MHC interactions.

Authors:  Qinghua He; Xianhan Jiang; Xinke Zhou; Jinsheng Weng
Journal:  J Hematol Oncol       Date:  2019-12-18       Impact factor: 17.388

6.  Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD.

Authors:  F He; E Warlick; J S Miller; M MacMillan; M R Verneris; Q Cao; D Weisdorf
Journal:  Bone Marrow Transplant       Date:  2016-04-11       Impact factor: 5.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.